These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14700343)

  • 41. [Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from Polish two-drug combination capsules of rifamazid used for tuberculosis treatment].
    Zofia Z; Niemirowska-Mikulska H; Augustynowicz-Kopeć E; Stambrowska A
    Pneumonol Alergol Pol; 1998; 66(3-4):198-206. PubMed ID: 9857665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-tuberculosis drugs and human polymorphonuclear leukocyte functions.
    Kielland LG; Vage RA; Eide GE; Sørnes S; Naess A
    Chemotherapy; 2011; 57(4):339-44. PubMed ID: 21912116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jul; 9(7):791-6. PubMed ID: 16013776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
    J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subchronic toxicity of human immunodeficiency virus and tuberculosis combination therapies in B6C3F1 mice.
    Rao GN; Lindamood C; Heath JE; Farnell DR; Giles HD
    Toxicol Sci; 1998 Sep; 45(1):113-27. PubMed ID: 9848118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.
    Gabriels GA; McIlleron H; Smith PJ; Folb PI; Fourie PB
    Int J Tuberc Lung Dis; 2007 Feb; 11(2):181-8. PubMed ID: 17263289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
    Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
    Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    Jindani A; Doré CJ; Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1348-54. PubMed ID: 12519740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
    Ellard GA; Ellard DR; Allen BW; Girling DJ; Nunn AJ; Teo SK; Tan TH; Ng HK; Chan SL
    Am Rev Respir Dis; 1986 Jun; 133(6):1076-80. PubMed ID: 3717760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.